PL3402474T3 - Inhibitory il-8 do zastosowania w leczeniu wywołanej chemioterapią neuropatii obwodowej - Google Patents

Inhibitory il-8 do zastosowania w leczeniu wywołanej chemioterapią neuropatii obwodowej

Info

Publication number
PL3402474T3
PL3402474T3 PL17701646T PL17701646T PL3402474T3 PL 3402474 T3 PL3402474 T3 PL 3402474T3 PL 17701646 T PL17701646 T PL 17701646T PL 17701646 T PL17701646 T PL 17701646T PL 3402474 T3 PL3402474 T3 PL 3402474T3
Authority
PL
Poland
Prior art keywords
inhibitors
treatment
peripheral neuropathy
chemotherapy induced
induced peripheral
Prior art date
Application number
PL17701646T
Other languages
English (en)
Polish (pl)
Inventor
Laura Brandolini
Pier Adelchi Ruffini
Marcello Allegretti
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16151618.2A external-priority patent/EP3192504A1/en
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of PL3402474T3 publication Critical patent/PL3402474T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17701646T 2016-01-15 2017-01-13 Inhibitory il-8 do zastosowania w leczeniu wywołanej chemioterapią neuropatii obwodowej PL3402474T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16151618.2A EP3192504A1 (en) 2016-01-15 2016-01-15 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP16190871 2016-09-27
PCT/EP2017/050637 WO2017121838A1 (en) 2016-01-15 2017-01-13 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP17701646.6A EP3402474B1 (en) 2016-01-15 2017-01-13 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

Publications (1)

Publication Number Publication Date
PL3402474T3 true PL3402474T3 (pl) 2021-12-27

Family

ID=57906595

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17701646T PL3402474T3 (pl) 2016-01-15 2017-01-13 Inhibitory il-8 do zastosowania w leczeniu wywołanej chemioterapią neuropatii obwodowej

Country Status (23)

Country Link
US (2) US12268671B2 (enExample)
EP (1) EP3402474B1 (enExample)
JP (1) JP7049254B2 (enExample)
KR (1) KR102737378B1 (enExample)
CN (1) CN108463219B (enExample)
AU (1) AU2017207850B2 (enExample)
CA (1) CA3009438A1 (enExample)
CY (1) CY1125297T1 (enExample)
DK (1) DK3402474T3 (enExample)
ES (1) ES2893701T3 (enExample)
HR (1) HRP20211527T1 (enExample)
HU (1) HUE056606T2 (enExample)
IL (1) IL260373B (enExample)
LT (1) LT3402474T (enExample)
MA (1) MA43861A (enExample)
MX (1) MX388815B (enExample)
PL (1) PL3402474T3 (enExample)
RS (1) RS62427B1 (enExample)
SG (1) SG11201804484YA (enExample)
SI (1) SI3402474T1 (enExample)
SM (1) SMT202100571T1 (enExample)
WO (1) WO2017121838A1 (enExample)
ZA (1) ZA201803486B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101914358B1 (ko) * 2017-01-18 2018-11-02 현대로템 주식회사 실내등 제어회로 및 이를 포함하는 철도차량
CN111343973A (zh) * 2017-10-24 2020-06-26 多姆皮制药公司 用于治疗一些肉瘤的il-8抑制剂
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
CA3196979A1 (en) * 2020-11-05 2022-05-12 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (en) * 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4397305A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
HRP20090681T1 (hr) 2004-03-23 2010-02-28 Dompe' S.P.A. Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže
EP2066335A4 (en) * 2006-09-26 2010-01-20 Univ Case Western Reserve ZYTOKINSIGNALISIERUNG
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
CR20160557A (es) 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
KR20170036753A (ko) * 2014-07-31 2017-04-03 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학요법 유도된 말초 신경병증 (cipn)의 예방 및/또는 치료를 위한 cxcr2 길항제의 용도

Also Published As

Publication number Publication date
US12268671B2 (en) 2025-04-08
MX2018008614A (es) 2018-11-19
CN108463219A (zh) 2018-08-28
CA3009438A1 (en) 2017-07-20
US20250195479A1 (en) 2025-06-19
EP3402474A1 (en) 2018-11-21
SI3402474T1 (sl) 2021-12-31
AU2017207850A1 (en) 2018-06-21
SMT202100571T1 (it) 2021-11-12
BR112018013570A2 (pt) 2018-12-11
ES2893701T3 (es) 2022-02-09
DK3402474T3 (da) 2021-10-11
LT3402474T (lt) 2021-11-25
MA43861A (fr) 2021-05-05
MX388815B (es) 2025-03-20
KR20180101390A (ko) 2018-09-12
HRP20211527T1 (hr) 2021-12-24
RS62427B1 (sr) 2021-11-30
SG11201804484YA (en) 2018-07-30
CY1125297T1 (el) 2023-03-24
AU2017207850B2 (en) 2022-06-30
ZA201803486B (en) 2019-09-25
NZ743344A (en) 2024-05-31
WO2017121838A1 (en) 2017-07-20
US20190015391A1 (en) 2019-01-17
JP2019501948A (ja) 2019-01-24
CN108463219B (zh) 2021-09-17
EP3402474B1 (en) 2021-07-21
JP7049254B2 (ja) 2022-04-06
HUE056606T2 (hu) 2022-02-28
IL260373B (en) 2021-03-25
KR102737378B1 (ko) 2024-12-04

Similar Documents

Publication Publication Date Title
IL263586B (en) Inhibitors of the menin-mll interaction
HUE060078T2 (hu) CDK7 gátlására alkalmas vegyületek
EP3488001A4 (en) TREATMENT OF CANCER
DK3445767T3 (da) Makrocykliske mcl1-inhibitorer til behandling af cancer
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
DK3515937T3 (da) Behandling af refraktorisk migræne
EP3377059A4 (en) INHIBITORS OF CXCR2
PL3154989T3 (pl) Inhibitory beta-laktamaz
HRP20190407T1 (hr) Heteroarilni spojevi za inhibiciju kinaza
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
EP3288383A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3310776A4 (en) BRUTON TYROSINE KINASE HEMMER
DK3442972T3 (da) Bromdomænehæmmere
IL269540A (en) Purification of phycobiliproteins
HUE056287T2 (hu) Pancreatitis kezelése
PL3157534T3 (pl) Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
PL3303654T3 (pl) Podstawione w pozycji 2 benzimidazolowe inhibitory korozji
IL261047A (en) Taf1 inhibitors for the therapy of cancer
EP3341080A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3389634A4 (en) METHOD FOR THE TREATMENT OF CANCER
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
LT3402474T (lt) Il-8 inhibitoriai, skirti panaudoti chemoterapijos sukeltos periferinės neuropatijos gydymui
PL3393468T3 (pl) Metody leczenia niedoboru odporności
DK3318115T3 (da) Maskine til behandling af svinegylle
PL3552017T3 (pl) Związki użyteczne jako inhibitory RIPK1